Large-scale gene expression profiling reveals distinct type 2 inflammatory patterns in chronic rhinosinusitis subtypes - 19/04/17
Doi : 10.1016/j.jaci.2016.09.048
Matthew A. Tyler, MD a, Chris B. Russell, PhD b, Dirk E. Smith, MSc c, James B. Rottman, DVM, PhD d, Caroline J. Padro Dietz, PhD a, e, Xuguang Hu, PhD b, Martin J. Citardi, MD a, Samer Fakhri, MD a, f, Shervin Assassi, MD g, Amber Luong, MD, PhD a, e 
a University of Texas McGovern Medical School, Department of Otorhinolaryngology-Head & Neck Surgery and Texas Sinus Institute, Houston, Tex
b Department of Medical Sciences, Amgen, Seattle, Wash
c Department of Inflammation Research, Amgen, Seattle, Wash
d Department of Pathology, Amgen, Cambridge, Mass
e University of Texas McGovern Medical School, Center for Immunology and Autoimmune Diseases, Institute of Molecular Medicine, Houston, Tex
f Department of Otolaryngology-Head and neck Surgery, American University of Beirut, Beirut, Lebanon
g Division of Rheumatology, University of Texas McGovern Medical School, Houston, Tex
| The cost of the microarray processing was partially supported by Amgen. A.L. is supported by the Center for Clinical and Translational Sciences, which is funded by National Institutes of Health Clinical and Translational Award UL1 TR000371 and KL2 TR000370 from the National Center for Advancing Translational Science. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Center for Advancing Translational Science or the National Institutes of Health. |
|
| Disclosure of potential conflict of interest: The Department of Otorhinolaryngology at the University of Texas McGovern Medical School received industry research funding from Allakos, Amgen, and IntersectENT. C. B. Russell is employed by Amgen, has patents through Amgen, and has stock/stock options with Amgen. D. E. Smith was employed by and owned stock in Amgen. J. B. Rottman was employed by Amgen and received stock/stock options from Amgen. C. J. Padro Dietz is employed by UTHealth. X. Hu is employed by and has stock/stock options with Amgen. M. J. Citardi has consultant arrangements with JNJ/Acclarent, Medtronic, and Medical Metrics and has had his laboratory sponsored by Karl Storz and Entellus. S. Fakhri has consultant arrangements with IntersectENT and has stock/stock options with ENTvantage Dx. A. Luong has a board membership with ENTvantage; has consultant arrangements with Medtronic, Laurimed LLC, 480 Biomedical, ENTvantagm, and Aerin Medical; has received grants from Amgen; and has received stock/stock options from ENTvantage and Laurimed LLC. The rest of the authors declare that they have no relevant conflicts of interest. |
© 2016
American Academy of Allergy, Asthma & Immunology. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 139 - N° 3
P. 1061 - marzo 2017 Ritorno al numero
Articolo precedente
- Serum autoreactivity predicts time to response to omalizumab therapy in chronic spontaneous urticaria
- Janine Gericke, Martin Metz, Tatevik Ohanyan, Karsten Weller, Sabine Altrichter, Per Stahl Skov, Sidsel Falkencrone, Janko Brand, Arno Kromminga, Tomasz Hawro, Martin K. Church, Marcus Maurer
- Multiplex platform technology and bioinformatics are essential for development of biomarkers in atopic dermatitis
- Judith L. Thijs, Athula Herath, Marjolein S. de Bruin-Weller, DirkJan Hijnen
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.
Già abbonato a @@106933@@ rivista ?